Skip to content
Running a protocolLesson 1 of 74 min

Baseline bloodwork

Baseline bloodwork before starting peptides

The dose math, a reminder before each dose and the log of what you took, in one app: Claritide for iPhone.

You cannot evaluate an "after" without a "before"

This is the step people skip, and skipping it makes the entire protocol uninterpretable. If your energy improves at week six, was that the compound, the season, better sleep, or nothing at all? Bloodwork is one of the few places you get an answer that is not a feeling.

The minimum panel

The Playbook's baseline set, drawn before your first dose:

IGF-1: the growth hormone marker. Essential for anything touching the GH axis, and useful as a general reference point.

Complete metabolic panel (CMP): glucose, liver enzymes (ALT, AST), kidney function (creatinine, BUN), electrolytes.

Complete blood count (CBC): white cells, red cells, haemoglobin.

Lipid panel: total cholesterol, LDL, HDL, triglycerides.

The retest schedule

Draw 1: baseline, before starting. Draw 2: week 4. Draw 3: week 8, or end of cycle. Draw 4: post-cycle, optional.

Four draws sounds like a lot. In practice, for a single 4–6 week cycle, baseline and end-of-cycle is the realistic minimum, and week 4 becomes important on longer protocols or anything affecting glucose.

Why each marker earns its place

IGF-1 is the readout for GH secretagogues. Tesamorelin's monitoring guidance is explicit: check IGF-1 periodically to ensure levels stay within the normal range. Elevated IGF-1 is the signal that you have overshot physiological replacement into something else.

Fasting glucose and HbA1c matter because several compounds move blood sugar, and not all in the same direction. Growth hormone increases insulin resistance and raises glucose. MOTS-C enhances glucose uptake and lowers it. Glucose elevation is one of the Playbook's named reasons to stop tesamorelin.

Liver enzymes matter because tesamorelin and retatrutide both affect hepatic fat, and because ALT and AST are the general-purpose early warning for a lot of things going wrong.

Lipids improve on several of these protocols, and that improvement is one of the more objective signs that a metabolic compound is doing something.

CBC is the broad safety net.

Reference ranges are your lab's, not ours

The Playbook's bloodwork tracker prints a "Reference Range" column deliberately left blank for you to fill in.

That is not an oversight. Reference intervals are assay-specific and laboratory-specific. The normal range for IGF-1 at one lab is not the normal range at another, and it varies by age and sex. Copy the range printed on your own report.

Claritide does the same thing. We do not ship reference ranges we cannot source, because a number that looks authoritative and is wrong is worse than a blank field.

Tell your provider

Bloodwork is also the natural moment to have the conversation the Playbook asks for: drug interactions with peptides are understudied, and if you take any medication your doctor needs the full picture, especially blood pressure medication, diabetes medication, CNS depressants or immunosuppressants.

Turning up with a panel and a list of what you intend to run is a far better conversation than turning up six weeks in with a symptom.

Check yourself

2 questions before you move on

  1. 1.What four categories make up the Playbook baseline panel?

  2. 2.Why does the Playbook leave the reference range column blank?

Every lesson here is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.